Jakafi is a brand name of Ruxolitinib, a prescription medicine. The FDA NDC Directory lists 5 Jakafi products in 5 strengths and forms.

Incyte Corp holds the FDA application for Jakafi (NDA202192, approved November 16, 2011).

Is there a generic or store brand of Jakafi?

Other products of Ruxolitinib are listed with the FDA, but none in exactly the same strength and form as a Jakafi product.

Jakafi (Ruxolitinib): maker, FDA approval and generic versions

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Jakafi?: Jakafi is a brand name of Ruxolitinib, a prescription medicine. The FDA NDC Directory lists 5 Jakafi products in 5 strengths and forms.
Who makes Jakafi?: Incyte Corp holds the FDA application for Jakafi (NDA202192, approved November 16, 2011).
Is there a generic or store brand of Jakafi?: Other products of Ruxolitinib are listed with the FDA, but none in exactly the same strength and form as a Jakafi product.
Has Jakafi been recalled?: No recall linked to Jakafi products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Jakafi is

Each Jakafi product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Ruxolitinib · prescription medicine

Strength and form	Product names	Same medicine, other names	Label
ruxolitinib 10 mg tablet (oral)	Jakafi	None listed	DailyMed
ruxolitinib 15 mg tablet (oral)	Jakafi	None listed	DailyMed
ruxolitinib 20 mg tablet (oral)	Jakafi	None listed	DailyMed
ruxolitinib 25 mg tablet (oral)	Jakafi	None listed	DailyMed
ruxolitinib 5 mg tablet (oral)	Jakafi	None listed	DailyMed

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Ruxolitinib →

FDA approval

NDA: New Drug Application: how a new (usually brand-name) medicine is approved.

FDA applications of Jakafi products (Drugs@FDA)
Application	Holder	First approved	Products
NDA202192	Incyte Corp	November 16, 2011	5

Companies that list Jakafi

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Jakafi products.

Incyte Corporation5 products

Recalls

No recall linked to Jakafi products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers

Jakafi